1h Free Analyst Time
The alzheimers disease therapeutics market is forecasted to grow by USD 5.98 billion during 2024-2029, accelerating at a CAGR of 10.2% during the forecast period. The report on the alzheimers disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability, research, and development of novel biomarkers, increasing awareness of alzheimers disease, and strong pipeline coupled with approval of therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The alzheimers disease therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- E-commerce pharmacy
By Drug Class
- Cholinesterase inhibitors
- N-methyl-D-aspartate receptor antagonist
- Others
By Therapeutic Area
- Symptomatic treatments
- Disease-modifying therapies
- Immunotherapies
- Gene therapies
- Small molecule inhibitors
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the alzheimers disease therapeutics market covers the following areas:
- Alzheimers Disease Therapeutics Market sizing
- Alzheimers Disease Therapeutics Market forecast
- Alzheimers Disease Therapeutics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Distribution Channel
9 Market Segmentation by Drug Class
10 Market Segmentation by Therapeutic Area
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global alzheimers disease therapeutics market: AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Cipla Inc., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emergence of regenerative therapies."
According to the report, one of the major drivers for this market is the availability, research, and development of novel biomarkers.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AbbVie Inc.
- AgeneBio Inc.
- Aurobindo Pharma Ltd.
- Biogen Inc.
- Cipla Inc.
- Curasia Medilab
- Denali Therapeutics Inc.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Grifols SA
- H Lundbeck AS
- Johnson and Johnson
- Lifecare Neuro Products Ltd.
- Lupin Ltd.
- Novartis AG
- Pfizer Inc.
- Psycogen Captab
- Solco Healthcare
- Teva Pharmaceutical Industries Ltd.
